🎯今日專家　林曉旭博士

首個FDA批准幼兒新冠療法，臨床試驗結果驚人！有常見肝損傷問題、可能引起急性腎衰竭！禁忌研究進行中！恐帶來更危險變種？

🎯數據來源

1. Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children

2. Press Release – Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

3. 1 PATIENT INFORMATION VEKLURY®

4. Frequently Asked Questions for Veklury (remdesivir)

5. Remdesivir for the Treatment of Covid-19 — Final Report

6. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

7. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

8. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database

9. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

10. Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN)

11. Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

功能增益研究

12. Genetic Mutation of SARS-CoV-2 during Consecutive Passages in Permissive Cells

13. SARS-CoV-2 Rapidly Adapts in Aged BALB/c Mice and Induces Typical Pneumonia

14. Isolation and Identification of a Rare Spike Gene Double-Deletion SARS-CoV-2 Variant From the Patient With High Cycle Threshold Value